Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$27.66 USD
+0.13 (0.47%)
Updated May 14, 2024 04:00 PM ET
After-Market: $27.71 +0.05 (0.18%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 201 - 218 ( 218 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Two Data Readouts in 1H15; Reiterating Market Outperform
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 2Q14 EPS; Advancing CORT-125 in August
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 1Q14 EPS; Lowering Price Target to $6
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Orphan Drug Play with Significant Upside Potential
Provider: BRINSON PATRICK SECURITIES CORPORATION